Clinical findings on active ingredients

Guaifenesin is an expectorant that is an active ingredient in most MUCINEX® products, and has provided powerful and trusted relief from mucus-related issues for 60 years.*

We’ve compiled a list of recent and relevant studies that demonstrate the efficacy and tolerability of guaifenesin. Please note that the links below will direct you to external websites.

In Vitro data

Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells

See the study

Seagrave JC, Albrecht H, Park YS, et al.

Exp Lung Res. 2011;37(10):606-614.

Results from an in vitro study* suggest that guaifenesin could improve mucociliary clearance in humans by reducing the release and/or production of mucins, thereby altering mucus rheology.

*Using primary human airway epithelial cells differentiated by air-liquid interface culture. These cultures are a complex, organotypic human airway model, containing the major cell types: basal, ciliated, non-ciliated and goblet cells.

Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells

See the study

Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G.

Respir Res. 2012;13:98.

Results from another in vitro study using airway cells demonstrate that guaifenesin effectively reduces cellular content and secretion of MUC5AC, increases MTR, and alters mucus rheology, and may therefore be useful in treating airway mucus hypersecretion and mucostasis in airway diseases.


Acute Respiratory Infections

Resolution of symptoms in patients with acute respiratory infections (ARI) receiving antibiotic therapy and MUCINEX® D

See the poster

LaForce C, Skoner D.

Results from a multicenter, randomized, parallel-group, double-blind, placebo-controlled study showed that when used in combination with antibiotic therapy in patients with acute respiratory infections, MUCINEX® D was well tolerated, shortened time to relief, and improved respiratory symptoms better than placebo.


Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

See the study

Albrecht H, Vernon M, Solomon G.

Respir Res. 2012;13:118.

Results from the study show that the scores from the 8 symptom-related questions in the Daily Cough and Phlegm Diary were robust and suitably reliable for use as efficacy endpoints in studies of expectorants, such as guaifenesin, for the symptoms of acute upper respiratory tract infections.


Guaifenesin and pseudoephedrine in an extended-release bi-layer tablet as first-line symptomatic therapy in patients with acute upper respiratory tract infections (URI): A randomized, double-blind, placebo-controlled, multicenter, parallel-group study

See the poster

Mariano Jr HG, Solomon G, Steward EC, Albrecht HH

Results show that the combination of 1200 mg guaifenesin and 120 mg pseudoephedrine HCl in an extended-release bi-layer tablet formulation offers a well-tolerated first-line symptomatic treatment that physicians can offer to patients instead of an antibiotic prescription for upper respiratory tract infections. A "wait and see" approach using a symptom-relieving product may reduce patients' desire for antibiotics and offer an alternative treatment without compromising patient satisfaction.


Cough Reflex Sensitivity

Effect of guaifenesin on cough reflex sensitivity

See the study

Dicpinigaitis PV, Gayle YE.

Chest. 2003;124(6):2178-2181.

Results demonstrate that guaifenesin inhibits cough reflex sensitivity in subjects with upper respiratory tract infections whose cough receptors are transiently hypersensitive, but not in healthy volunteers.


Quality of Life

Quality of life in patients taking guaifenesin and pseudoephedrine in an extended-release bi-layer tablet as first-line symptomatic therapy for acute upper respiratory tract infections (URI)

Mariano Jr HG, Solomon G, Steward EC, Albrecht HH

Results indicate that for the treatment of urinary tract infections, the combination of 1200 mg guaifenesin and 120 mg pseudoephedrine HCl in an extended-release bi-layer tablet formulation provides symptom relief, helps patients feel better and experience improved QoL faster, and therefore may help reduce the imprudent use of antibiotics.


Mothers’ and school nurses’ assessment of cough and cold impact on children’s quality of life

See the press release
See the fact sheet
See the abstract
See the poster

Flint LE, Morrissey M, Whipple JR

Survey results show that the cold and cough season can impact the quality of life for school-aged children, as observed by mothers and school nurses.


Stable Chronic Bronchitis

Approved healthcare professional labeling for MUCINEX® supports guaifenesin’s ability to help loosen phlegm and thin bronchial secretions in patients with Stable Chronic Bronchitis (SCB)†ǂ

See the supporting data

Presenting Author: Kim KC

Study results support guaifenesin’s effect on mucin production, rheology, and mucociliary transportability in fully differentiated human epithelial cells.


*Source: Suneetha G, Venkateswarlu P, Prasad PSS. Determination of guaifensen and dextromethorphan by UPLC. Der Pharma Chemica. 2012; 4(3):1019-1025.
†Source: Drugs.com Statistics, Q4 2011 (http://www.drugs.com/stats/top100/2011/q4/sales).
ǂGuaifenesin products indicated for the treatment of stable chronic bronchitis are available only by prescription.